Cidara Therapeutics Inc. (CDTX)

$44.95

up-down-arrow $23.93 (113.84%)

As on 23-Jun-2025 16:28EDT

Cidara Therapeutics Inc. (CDTX) Share Price

Compare

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

loading...
loading...
loading...
loading...
loading...
loading...
loading...
loading...

Stock Range

Today’s Range

Low: 37.76 High: 45.39

52 Week Range

Low: 10.14 High: 45.39

Liquidityliquidity High

Low Moderate High

Fundamentals

  • Market capMarket cap information

    $273 Mln

  • Revenue (TTM)Revenue (TTM) information

    $0 Mln

  • Net Profit (TTM)Net Profit (TTM) information

    $0 Mln

  • ROEROE information

    -3 %

  • ROCEROCE information

    -- %

  • P/E RatioP/E Ratio information

    --

  • P/B RatioP/B Ratio information

    1.9

  • Industry P/EIndustry P/E information

    --

  • EV/EBITDAEV/EBITDA information

    -1.6

  • Div. YieldDiv. Yield information

    0 %

  • Debt to EquityDebt to Equity information

    0

  • Book ValueBook Value information

    $--

  • EPSEPS information

    $-29

  • Face valueFace value information

    --

  • Shares outstandingShares outstanding information

    12,969,800

10 Years Aggregate

CFO

$-339.13 Mln

EBITDA

$-420.07 Mln

Net Profit

$-416.09 Mln

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Cidara Therapeutics (CDTX)
67.2 74.9 100.0 286.8 339.4 62.8 11.5
BSE Sensex*
4.9 0.4 6.7 6.3 16.2 18.3 11.4
S&P Small-Cap 600#
-5.8 -5.3 -13.7 -6.3 5.3 3.0 5.5
As on 23-Jun-2025  |  *As on 24-Jun-2025  |  #As on 26-Oct-2023
Company
2024
2023
2022
2021
2020
2019
2018
Cidara Therapeutics (CDTX)
3,189.6 5.0 -40.5 -36.5 -47.9 63.4 -65.2
S&P Small-Cap 600
7.0 13.9 -17.4 25.3 9.6 20.9 -9.7
BSE Sensex
8.1 18.7 4.4 22.0 15.8 14.4 5.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

Key Ratios

View Details
loading...

loading...

loading...

5Y Avg -- 3Y Avg -- TTM --

loading...

P/E Ratio

--

--Min --Median --Max

loading...

P/B Ratio

--

--Min --Median --Max

loading...

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

loading...

loading...

loading...

Peers

View Details
Company
Price ($) Market Cap ($ Mln) Revenue (TTM) Net Profit (TTM) OPM (%) ROE (%) P/E P/B
Cidara Therapeutics (CDTX)
45.0 272.6 0.3 -180.7 -35,750.3 -140.5 -- 1.9
49.3 7,821.1 1,208.8 131.7 13.4 6.3 60.1 3.9
128.4 8,290.2 562.1 -155.7 -19.3 -47.5 -- 24.2
147.4 7,242.1 4,022.6 -31.6 3.7 -1.1 -- 2.3
52.5 10,001.6 2,828.1 -1,019.8 -36.2 -36.4 -- 4.2
43.4 11,009.2 2,298.9 643.6 35.4 29.2 18.4 5.2
52.8 6,507.3 1,084.3 485.4 57.0 103.8 14 13.5
308.6 8,891.5 2,156.6 416.4 21.2 56.5 23.6 15.0
25.7 10,016.6 3,159.0 -3,357.0 -76.7 -30.5 -- 1.0
125.8 12,524.1 2,412.6 305.8 20.5 11.6 42.9 4.9

Shareholding Pattern

View Details
loading...

About Cidara Therapeutics Inc. (CDTX)

Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the...  echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California. Address: 6310 Nancy Ridge Drive, San Diego, CA, United States, 92121  Read more

  • President, CEO & Executive Director

    Dr. Jeffrey L. Stein Ph.D.

  • President, CEO & Executive Director

    Dr. Jeffrey L. Stein Ph.D.

  • Headquarters

    San Diego, CA

  • Website

    https://www.cidara.com

Edit peer-selector-edit
loading...
loading...

FAQs for Cidara Therapeutics Inc. (CDTX)

The total asset value of Cidara Therapeutics Inc (CDTX) stood at $ 241 Mln as on 31-Mar-25

The share price of Cidara Therapeutics Inc (CDTX) is $44.95 (NASDAQ) as of 23-Jun-2025 16:28 EDT. Cidara Therapeutics Inc (CDTX) has given a return of 339.36% in the last 3 years.

Cidara Therapeutics Inc (CDTX) has a market capitalisation of $ 273 Mln as on 23-Jun-2025. As per Value Research classification, it is a Small Cap company.

The P/B ratio of Cidara Therapeutics Inc (CDTX) is 1.92 times as on 23-Jun-2025, a 31% discount to its peers’ median range of 2.79 times.

Since, TTM earnings of Cidara Therapeutics Inc (CDTX) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Cidara Therapeutics Inc (CDTX) and enter the required number of quantities and click on buy to purchase the shares of Cidara Therapeutics Inc (CDTX).

Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California. Address: 6310 Nancy Ridge Drive, San Diego, CA, United States, 92121

The CEO & director of Dr. Jeffrey L. Stein Ph.D.. is Cidara Therapeutics Inc (CDTX), and CFO & Sr. VP is Dr. Jeffrey L. Stein Ph.D..

There is no promoter pledging in Cidara Therapeutics Inc (CDTX).

Cidara Therapeutics Inc. (CDTX) Ratios
Return on equity(%)
-140.48
Operating margin(%)
-35750.33
Net Margin(%)
-59845.03
Dividend yield(%)
--

No, TTM profit after tax of Cidara Therapeutics Inc (CDTX) was $0 Mln.